Article
Sanger sequencing versus INNO-LiPA® HBV PreCore assay for routine detection of precore and basal core promoter mutations in hepatitis virus B chronically infected patients.
Diagnostic microbiology and infectious disease - 1 Apr 2018
Alidjinou E K, Bocket L, Pigot V, Lambert V, Hallaert C, Canva V, Hober D
Abstract excerpt
We compared the Sanger sequencing and the commercial INNO-LiPA® HBV assay for the routine detection of precore (PC) and basal core promoter (BCP) mutations of hepatitis B virus in chronically infected patients. The overall agreement rate between assays was 94.2% and 98.8% for the detection of PC and BCP mutations, respectively.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.